Dilucort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilucort

Quick Facts: Hydrocortisone

Property Description
Active Ingredient Hydrocortisone (or Hydrocortisone Acetate)
Common Forms Cream, Ointment, Tablet, Solution for injection
Pharmacological Class Corticosteroid (Glucocorticoid)
General Purpose Controlling inflammation and immune response
Origin Semi-synthetic (derived from natural Cortisol)

What Type of Medicine is Dilucort and its Core Identity?

Dilucort is a pharmaceutical preparation containing the active ingredient Hydrocortisone, which is chemically defined and categorized as a potent Glucocorticoid or Adrenocortical steroid. This substance is clinically recognized across numerous international pharmacopoeias as a semi-synthetic Corticosteroid, meaning it is manufactured to precisely replicate the biological effects of Cortisol, the essential steroid hormone naturally produced by the human adrenal glands. This core identity places Hydrocortisone as a compound capable of broadly and profoundly regulating the body's internal inflammatory and immune processes.

The pharmacological function of any Glucocorticoid is achieved through the modulation of gene expression within cells, which acts to immediately interrupt and inhibit the complex cascade of inflammatory and immune mediators. Hydrocortisone possesses a balanced profile, exhibiting strong glucocorticoid activity and some mild mineralocorticoid effect. This characteristic distinguishes it from more specialized synthetic analogues designed for pure immune suppression.

Hydrocortisone Composition, Forms, and General Purpose

The medication is composed of the single active ingredient Hydrocortisone, frequently delivered as its ester, Hydrocortisone Acetate, which is then integrated into various pharmaceutical bases or vehicles. The availability of Hydrocortisone is highly versatile, featuring multiple dosage forms, including oral tablets, topical creams and ointments, and sterile solutions for parenteral (injection) administration. The specific formulation of these products—such as the inclusion of soft paraffins for occlusive ointments versus emulsifying wax for water-based creams—ensures targeted absorption and delivery.

This broad pharmacological type and versatile formulation establish its overall therapeutic utility: the general purpose is to provide powerful, comprehensive relief by controlling systemic inflammation and suppressing the exaggerated activity of the body's own immune system. By acting at this foundational level, Hydrocortisone is fundamentally designed to alleviate the symptoms, such as swelling and discomfort, that result directly from profound tissue inflammation and immunological imbalance.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Dilucort?

Possible Side Effects and Safety Information for Dilucort

The safety profile of Hydrocortisone (Dilucort) is officially documented by government regulatory agencies (such as the FDA and EMA) and reflects the systemic effects of the Glucocorticoid pharmacological class. Adverse reactions are primarily categorized by the System-Organ-Class (SOC) affected and by their frequency.

Key adverse reaction categories officially listed include Endocrine Disorders (such as HPA axis suppression), Metabolic Disorders (like fluid retention and changes in glucose tolerance), Musculoskeletal effects (e.g., osteoporosis), and Psychiatric disturbances (including mood changes and insomnia).

Many effects are often associated with the duration of use. Reactions like osteoporosis and the formation of posterior subcapsular cataracts are primarily linked to long-term use or higher doses. Conversely, the critical risk of adrenal crisis is primarily associated with withdrawal or abrupt discontinuation of therapy, which can occur after prolonged use.

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions highlighted in regulatory documents include the risk of Severe Infection (due to immune suppression) and Gastrointestinal Perforation in susceptible patients. The medicine is formally contraindicated in individuals with a known history of Systemic Fungal Infections.

Population-specific safety considerations are also noted. For pediatric patients, regulatory documents identify the potential for linear growth retardation with chronic high-dose use. In older adults, the risk of developing certain effects, such as osteoporosis and hypertension, is noted as higher, consistent with background risk factors. The final safety structure is designed to communicate these officially classified risks without providing individual clinical advice.

Overdose and Emergency Response

Overdose and when to seek help

Overdose for Dilucort, which contains Hydrocortisone, is officially defined by the manifestations resulting from excessive glucocorticoid and mineralocorticoid activity, as documented in regulatory labeling. The symptom profile focuses on the physiological consequences of exposure exceeding the prescribed dose.

Acute systemic exposure is primarily associated with changes in the body's fluid and electrolyte balance, leading to documented manifestations such as the elevation of blood pressure, salt and water retention, and increased potassium excretion. Neurological signs that may be documented include altered mental status, agitation, or convulsions (seizures). Long-term high-dose exposure is officially associated with the development of clinical features resembling Cushing’s syndrome.

If an overdose is suspected, official guidance mandates that an individual get medical help right away. This includes explicitly calling emergency services or contacting a Poison Control center immediately. Urgent medical attention is necessary if severe manifestations, such as heart rhythm disturbances, are suspected.

Management is officially described as symptomatic and supportive treatment, given that a specific antidote is not listed in regulatory documentation. Monitoring requirements in an emergency setting may include measuring vital signs, performing blood and urine tests, and conducting an ECG. A population-specific note indicates that pediatric patients may be more susceptible to systemic toxicity.

Therapeutic Uses of Dilucort

What Dilucort Treats: Main Uses and Benefits

The medication is commonly used to help with adrenal hormone replacement and is applied in addressing severe inflammation driven by the immune system. It is commonly applied across various medical domains to help ease intense symptomatic discomfort and address critical physiological needs.

This medicine is considered relevant in conditions where symptoms may intensify temporarily, such as rheumatoid arthritis and lupus, active periods of inflammatory bowel disease (like ulcerative colitis), and severe allergic states.

The medication is generally used to manage clusters of symptoms that appear suddenly or fluctuate, including painful joint swelling, widespread tissue discomfort, severe itching, and symptoms related to adrenal hormone deficiency. It is often applied in clinical settings that involve acute or unstable symptom patterns. The overall benefit is that it assists with maintaining functional stability for those with hormone deficiency, and for patients with inflammatory conditions, it contributes to easing the overall symptom load when symptoms interfere with routine activities.


Quick Fact: Support for Inflammatory Symptoms

Symptom Axis Therapeutic Focus Primary Benefit
Inflammation Systemic or localized tissue redness and swelling Contributes to easing the overall symptom load
Allergy Acute, severe hypersensitivity reactions Supports patients during episodes of heightened discomfort
Hormone Deficiency Symptoms related to systemic imbalance and weakness Helps maintain a sense of stability

Regulatory References

  1. Official FDA Drug Label for Hydrocortisone

Eligibility and Restrictions for Use

Who Can and Cannot Use Dilucort?

Dilucort (Hydrocortisone) eligibility is defined by official regulatory rules detailing who can use the medicine and who is formally restricted or contraindicated. This information is based exclusively on government-approved labeling.


Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with an active Systemic Fungal Infection or a known Hypersensitivity to Hydrocortisone or any component of the specific preparation. Furthermore, specific injection forms are prohibited for use in Premature Infants and in patients with Idiopathic Thrombocytopenic Purpura (for intramuscular administration).


Restricted and Conditional Use

Use is restricted and requires official caution in patients with pre-existing conditions that may be exacerbated, including Diabetes Mellitus, Hypertension, Congestive Heart Failure, active or latent Peptic Ulcer Disease, and certain active infections. Caution is also warranted for patients with Ocular Herpes Simplex or Osteoporosis.


Age- and Maternal-Related Rules

Age-related eligibility notes that safety and efficacy are not established for some oral liquid forms in children younger than five years of age or for certain injection forms in infants one month of age or younger. Chronic use in the pediatric population may officially interfere with growth and development. For pregnant patients, systemic use is often classified as Category C by the FDA, and use is contingent upon the potential benefit justifying the risk; caution is advised for high-dose systemic use during lactation.

What should I know about interactions with other medicines?

The interaction profile for Dilucort is determined by how other medicinal products and substances affect its metabolism or its established physiological effects. The most significant interactions involve the CYP3A4 enzyme system.

Co-administration with CYP3A4 Inhibitors, such as certain antifungal medications (e.g., ketoconazole) or macrolide antibiotics (e.g., clarithromycin), is officially documented to inhibit the metabolism of Dilucort, which may increase its circulating concentration. Conversely, co-administration with CYP3A4 Inducers, including specific antiepileptic agents (e.g., phenytoin, phenobarbital) or Rifampicin, may enhance Dilucort's metabolism, resulting in reduced systemic exposure and potentially decreased efficacy.

Pharmacodynamic interactions describe additive or antagonistic effects. Dilucort’s action may antagonize the therapeutic effects of Antidiabetic Agents and Antihypertensives, reducing the intended outcome of those medicines. Furthermore, co-administration with Diuretics (e.g., thiazides) may enhance the risk of potassium loss.

A major restriction is the formal classification of Live or Live-Attenuated Vaccines as contraindicated when Dilucort is used at immunosuppressive doses. The product label also notes that consumption of grapefruit juice may act as a CYP3A4 inhibitor, potentially leading to increased circulating levels of Dilucort. Enhanced systemic effects are also noted in populations with co-existing conditions, such as liver disease (cirrhosis) and thyroid dysfunction.

Mechanism of Action

Genomic Reprogramming via the Glucocorticoid Receptor

Hydrocortisone's action begins by acting as an agonist at the intracellular Glucocorticoid Receptor (GR). The activated receptor complex then moves to the nucleus, where it profoundly alters gene expression through two processes: Transrepression, which silences the genetic commands for pro-inflammatory messengers like cytokines (TNF-alpha, IL-1), and Transactivation, which initiates the synthesis of natural anti-inflammatory proteins, such as Annexin A1. This central molecular mechanism alters cellular inflammatory pathways at the genetic level.

Modulating Inflammatory Pathways and Cell Function

The molecular actions lead to system-wide effects, primarily by suppressing the Arachidonic Acid Cascade (via indirect inhibition of Phospholipase A2) and influencing the migration of cellular elements. This results in a massive reduction of key inflammatory mediators like prostaglandins and leukotrienes at the tissue level. By also stabilizing capillary walls and promoting vasoconstriction, the mechanism results in decreased fluid extravasation and reduction in the movement of T-lymphocytes and macrophages into affected areas, thereby modulating the rate of change in local physiological responses.

Dosage and Administration Information

How Dilucort is Used: Official Administration Guidelines

Dilucort (Hydrocortisone) is administered according to regimens that vary widely based on the specific condition and formulation. The medicine is available across multiple administration routes, including oral forms (conventional tablets and modified-release forms), parenteral forms (intravenous and intramuscular), topical applications, and rectal preparations.


Official Dosing and Scheduling Patterns

Usage Context Administration Principle Frequency and Timing
Adrenal Replacement Maintenance doses typically range from 15 mg to 25 mg daily. Conventional tablets are taken in two or three divided doses per day.
Modified-Release Form The total daily dose is contained within this formulation. Administered once daily in the morning, usually upon waking, and must be taken at least 30 minutes before food.
Acute/High-Dose IV Initial doses start at 100 mg and may be repeated or infused. High-dose parenteral therapy is generally restricted to short-term use, often not exceeding 48 to 72 hours.

Administration Requirements

Specific instructions govern the proper intake of Dilucort. For example, modified-release tablets must be swallowed whole and must not be crushed, divided, or chewed, as this can alter the drug's release pattern. Parenteral solutions require dilution before administration and can be delivered as a slow injection or continuous infusion. The dosing for pediatric patients is frequently calculated based on body weight or body surface area (mg/kg/day or mg/m²/day), establishing a framework for age-specific use. Long-term regimens necessitate a gradual dose reduction (tapering) process when cessation is planned.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dilucort (Hydrocortisone)


Evidence Base for Adrenal Hormone Replacement

The research base for using this medicine in cases of adrenal insufficiency—a condition involving systemic or functional imbalance—has been extensively studied. Researchers have conducted numerous pharmacokinetic (PK) studies and comparative crossover trials. These studies primarily measure the resulting cortisol plasma concentration profiles in both adults and children with adrenal insufficiency, examining outcomes such as the total daily exposure to the drug (Area Under the Curve, AUC) and the response of the HPA axis.

Research has explored different formulations, documenting patterns in how these forms are associated with the timing and amount of the medicine in the blood. What remains uncertain is the optimal dosing protocol that precisely replicates the natural, fluctuating, 24-hour cortisol rhythm and how best to address patient-to-patient variability. Long-term data for certain overall health outcomes are still emerging.


Evidence for Systemic Inflammatory Conditions

The evidence for use in conditions characterized by fluctuating manifestations, such as active inflammatory bowel disease or rheumatoid arthritis flare-ups, has been explored through short-term Randomized Controlled Trials (RCTs). These trials are often relevant in research exploring episodic symptom patterns. Studies focus on periods of increased symptom activity and examined outcomes related to clinical disease severity scores, functional measures, and changes observed during endoscopic examinations.

Findings describe patterns observed in the studies related to measures of disease activity following a short course of the medicine. A key limitation is that many studies focus only on the initial, short-term phase of use, providing limited insight into the medication’s role for long-term maintenance or its influence on structural changes over many years.


Research Focus on Topical Applications

Research on the topical forms, relevant in trials assessing short-term localized symptom patterns, primarily involves short-term clinical trials and bioequivalence studies. These studies were evaluated in populations with corticosteroid-responsive dermatoses and monitored outcomes linked to inflammatory states, such as the severity of redness, scaling, and patient-reported itching (pruritus). The research predominantly examines short-term symptom outcomes and local effects, and data for certain groups, particularly those with altered skin barrier integrity, remains insufficient.

Key Studies & References

  1. Hydrocortisone (Oral Route) - Drug Information
  2. Hydrocortisone Oral Tablet (Systemic) - FDA Label

Frequently Asked Questions (FAQ)

Common questions about Dilucort (FAQ)

Q: Is Dilucort an anti-inflammatory or something else?

A: Dilucort contains Hydrocortisone, which is officially classified as a corticosteroid. According to regulatory documents, this medicine has two main types of action: it works to suppress inflammation and the immune response, and it is also used for hormone replacement in conditions where the body does not produce enough of its own cortisol.

Q: How quickly does Dilucort usually start working?

A: The speed at which the medicine begins to work depends heavily on the form used. For injection forms, demonstrable effects can be seen within one hour of administration. For the anti-inflammatory action, official information indicates that the onset of therapeutic action may take approximately 4 to 6 hours or longer.

Q: What's the expected time frame to see results from Dilucort?

A: While initial effects from injection forms can be observed quickly, the overall timeframe for seeing noticeable changes in symptoms may take time. Because this medicine regulates genetic processes, the speed of response varies greatly depending on the condition being treated and the route of administration.

Q: If I miss a dose of Dilucort, what do official documents say to do?

A: Regulatory guidance describes actions that may be taken if a dose is missed, such as taking the dose as soon as it is remembered unless it is near the next scheduled dose. Official documents advise against doubling a dose, emphasizing the need to follow the prescribed regimen.

Q: Is Dilucort meant for short-term use only?

A: The required duration of therapy is determined by the specific medical condition. For hormone replacement therapy (such as in Addison's disease), the medicine is typically used long-term, potentially lifelong. For other inflammatory conditions, official labeling indicates that shorter, focused courses may be prescribed.

Q: Is it normal to feel a bit restless when taking Dilucort?

A: Yes, official product information lists restlessness and insomnia (trouble sleeping) as possible side effects. Other documented psychic disturbances include mood changes, which can sometimes involve an unusual or false sense of well-being.

Q: Do many people report changes in appetite while on Dilucort?

A: Regulatory documents list an increased appetite as a common side effect of this class of medicine. Patients using this medication are advised that changes in metabolism are possible.

Q: Does Dilucort cause weight gain in most people?

A: Weight gain is officially listed as a possible side effect of the medicine. This may be related to changes in metabolism and the medicine's potential to cause the retention of fluid and sodium, particularly when used for prolonged periods.

Q: Are there any long-term health concerns associated with Dilucort?

A: Yes, official safety information links prolonged use to several potential health concerns. These may include bone thinning (osteoporosis), certain eye problems like cataracts and glaucoma, and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which is the body's natural hormone production system.

Q: Does Dilucort interact with birth control pills?

A: Regulatory warnings indicate a potential interaction between Dilucort and hormonal contraceptives. The official documents note that certain female hormones may increase the level of Dilucort in the bloodstream, which may be associated with an increased risk of side effects.

Q: Can people with liver issues use Dilucort?

A: Regulatory documents state that caution is necessary when this medicine is used by patients with liver conditions like cirrhosis, as reduced metabolism can lead to enhanced systemic effects. This is a population that requires careful consideration.

Q: What is the typical timeframe for getting Dilucort out of your system?

A: Official pharmacological data indicates that the medicine is largely eliminated from the body within about 12 hours of administration. However, the overall duration of its effects and the total time it takes for a full dose to clear the system depend on the specific formulation, dosage, and individual patient factors.

Q: Is there a generic version of Dilucort available?

A: The active ingredient in Dilucort is Hydrocortisone, which is a widely recognized generic compound. Hydrocortisone is available generically and is also marketed under various brand names around the world.

Q: Does Dilucort have any restrictions on driving or operating machinery?

A: Official information advises caution when driving or operating complex machinery, due to the possibility of experiencing side effects such as dizziness and unusual tiredness. These effects should be considered before engaging in these activities.

Q: Do patients typically take Dilucort long-term for chronic conditions?

A: Yes, Dilucort is often taken long-term for conditions that require chronic hormone replacement, such as Addison's disease. For other chronic inflammatory conditions, the duration of use varies, and regulatory documents highlight the need for careful management during prolonged therapy.

Q: Are there different strengths or formulations of Dilucort available?

A: Yes, official product information confirms that the medicine is available in multiple strengths for oral administration. It is also available in various physical forms, including standard tablets, modified-release tablets, and injectable solutions.

Q: Is Dilucort usage restricted for individuals with kidney problems?

A: Regulatory documents state that caution is necessary when this medicine is used by patients with renal (kidney) insufficiency, due to the possibility of sodium and fluid retention.

Q: Is Dilucort considered safe for children?

A: Dilucort is approved for use in children for specific conditions, including hormone replacement therapy, with dosing often based on body surface area. Official documents include warnings that chronic use of corticosteroids in the pediatric population may be associated with the suppression of growth and development.

Q: Does taking Dilucort make you more susceptible to infections?

A: Regulatory information states that this type of medicine may mask some common signs of infection. It is also associated with a decreased resistance to new infections and a reduced ability to localize existing infections.

Q: Is it true that Dilucort can affect mood or cause emotional changes?

A: Yes, official product information lists psychic disturbances and mood changes as possible side effects. These changes can include symptoms of depression or feeling highly energized. The risk of these effects is often noted to be higher with increased doses.

Q: Do any official documents list special monitoring or tests needed while on Dilucort?

A: Yes, for patients on prolonged therapy, official documents note that special monitoring may be necessary. These tests typically check for suppression of the HPA axis (the body's natural hormone production) or involve monitoring glucose levels.

How should Dilucort be stored and disposed of?

How to Store and Dispose of Dilucort

Dilucort must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Protect from moisture, freezing, and excessive heat.
Container Must be kept in a tight container and remain tightly closed.
Child Safety Store out of the reach of children.

Disposal Instructions

Unused or expired Dilucort should be disposed of in accordance with federal and local regulations. If a drug take-back program is not available, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in household trash. All identifying information on the prescription label must be removed before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilucort found in:

A-Z Index: